COVID-19 in multiple sclerosis patients treated with dimethyl fumarate
暂无分享，去创建一个
[1] Esben B. Svenningsen,et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate , 2020, Nature Communications.
[2] A. Conte,et al. The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia , 2020, Journal of Neuroimmunology.
[3] A. Salmaggi,et al. COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis , 2020, Journal of Neurology.
[4] M. Filippi,et al. COVID-19 in teriflunomide-treated patients with multiple sclerosis , 2020, Journal of Neurology.
[5] V. Meca-Lallana,et al. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population , 2020, Journal of Neurology.
[6] O. Ciccarelli,et al. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic , 2020, Neurology.
[7] F. Zipp,et al. IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis , 2019, Nature Communications.
[8] S. Zamvil,et al. Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate , 2015, Neurology: Neuroimmunology & Neuroinflammation.